Jordan V Craig
Fox Chase Cancer Centre, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Eur J Cancer. 2006 Nov;42(17):2909-13. doi: 10.1016/j.ejca.2006.09.012. Epub 2006 Oct 24.
The completion of the Study of Tamoxifen and Raloxifene (STAR) [Vogel VG, Costantino JP, Wickerham DL, et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 2006;295:2727-2741.] and the ongoing studies with aromatase inhibitors [Goss PE. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86(3-5):487-93.] to assess their worth for the chemoprevention of breast cancer, creates an opportunity to consider the realistic future for chemoprevention as an option for women's healthcare and to identify strategies for future progress in an era of targeted therapeutics, managed healthcare and soaring costs.
他莫昔芬与雷洛昔芬研究（STAR）[沃格尔·V·G、科斯坦蒂诺·J·P、威克勒姆·D·L等。他莫昔芬与雷洛昔芬研究（STAR）：国家外科辅助乳腺和肠道项目P - 2试验报告。《美国医学会杂志》2006年；295:2727 - 2741。]以及正在进行的关于芳香化酶抑制剂的研究[戈斯·P·E。乳腺癌预防——涉及芳香化酶抑制剂的临床试验策略。《类固醇生物化学与分子生物学杂志》2003年；86(3 - 5):487 - 93。]，旨在评估它们在乳腺癌化学预防中的价值，这为我们提供了一个机会，来思考化学预防作为女性医疗保健选择的现实未来，并确定在靶向治疗、管理式医疗和成本飙升的时代取得未来进展的策略。
